Hypercholesterolemia may lead to obesity and cardiovascular diseases. To prevent hypercholesterolemia, many drugs have been developed while searching for better drugs to treat hypercholesterolemia has never been ended. Other than small molecule drugs, peptide drugs are gaining more visibilities in many therapeutic areas. In the present study, we employed phage-display techniques to screen peptide inhibitors against human HMG-CoA reductase. The results indicate that the tetrapeptide PMAS inhibits hHMGR effectively (IC50=68 μM), could be a lead compound to develop hypocholesterolemic agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2014.11.042 | DOI Listing |
Publication Analysis
Top Keywords
peptide inhibitors
8
inhibitors human
8
human hmg-coa
8
hmg-coa reductase
8
reductase potential
4
potential hypocholesterolemia
4
hypocholesterolemia agents
4
agents hypercholesterolemia
4
hypercholesterolemia lead
4
lead obesity
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!